BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gkolfinopoulos S, Tsapakidis K, Papadimitriou K, Papamichael D, Kountourakis P. Chromogranin A as a valid marker in oncology: Clinical application or false hopes? World J Methodol 2017; 7(1): 9-15 [PMID: 28396845 DOI: 10.5662/wjm.v7.i1.9] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Davies MP, John Evans TW, Tahir F, Balasubramanian SP. Parathyroid cancer: A systematic review of diagnostic biomarkers. Surgeon 2021;19:e536-48. [PMID: 33642204 DOI: 10.1016/j.surge.2021.01.011] [Reference Citation Analysis]
2 Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas 2020;49:863-81. [PMID: 32675783 DOI: 10.1097/MPA.0000000000001597] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
3 Cheng J, Patel G, Dawood A, Aqeel A. Gastric and Duodenal Neuroendocrine Tumor Incidentally Found on Endoscopy During the Evaluation of Iron-Deficiency Anemia. Cureus. [DOI: 10.7759/cureus.22208] [Reference Citation Analysis]
4 Giridhar KV, Sanhueza C, Hillman DW, Alkhateeb H, Carlson R, Tan W, Costello BA, Quevedo F, Pagliaro L, Kohli M. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2018;21:431-7. [PMID: 29858590 DOI: 10.1038/s41391-018-0046-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
5 Kövesdi A, Kurucz PA, Nyírő G, Darvasi O, Patócs A, Butz H. Circulating miRNA Increases the Diagnostic Accuracy of Chromogranin A in Metastatic Pancreatic Neuroendocrine Tumors. Cancers (Basel) 2020;12:E2488. [PMID: 32887459 DOI: 10.3390/cancers12092488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kassas JM, Fiuk JV, Brenner CA. Primary Small Cell Carcinoma of the Bladder. Cureus 2021;13:e15146. [PMID: 34164246 DOI: 10.7759/cureus.15146] [Reference Citation Analysis]
7 Tomita T. Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors. Bosn J Basic Med Sci 2020;20:336-46. [PMID: 32020844 DOI: 10.17305/bjbms.2020.4632] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Szarvas T, Jardin-Watelet B, Bourgoin N, Hoffmann MJ, Nyirády P, Oláh C, Széll T, Csizmarik A, Hadaschik B, Reis H. High-soluble CGA levels are associated with poor survival in bladder cancer. Endocr Connect 2019;8:625-33. [PMID: 30999279 DOI: 10.1530/EC-19-0068] [Reference Citation Analysis]
9 Syed S, Basourakos SP, Ali FS, Garcia JL, Zurita-Saavedra A, Gong Z. A Limited-Versus-Extensive Staging Strategy for Small Cell Prostate Cancer. Am J Clin Oncol 2020;43:87-93. [PMID: 31764016 DOI: 10.1097/COC.0000000000000631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Gade AK, Olariu E, Douthit NT. Carcinoid Syndrome: A Review. Cureus. 2020;12:e7186. [PMID: 32257725 DOI: 10.7759/cureus.7186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Ciobanu OA, Martin S, Fica S. Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review). Exp Ther Med 2021;22:1479. [PMID: 34765020 DOI: 10.3892/etm.2021.10914] [Reference Citation Analysis]
12 Henry K. Paraneoplastic syndromes: Definitions, classification, pathophysiology and principles of treatment. Semin Diagn Pathol 2019;36:204-10. [PMID: 30876820 DOI: 10.1053/j.semdp.2019.01.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
13 Zhang D, Xie C, Wang R, Yang Q, Chen H, Ling S, Wang S, Jia K. Effective preparation of a monoclonal antibody against human chromogranin A for immunohistochemical diagnosis. BMC Biotechnol 2018;18:25. [PMID: 29728076 DOI: 10.1186/s12896-018-0436-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Öberg K, Califano A, Strosberg J, Ma S, Pape U, Bodei L, Kaltsas G, Toumpanakis C, Goldenring J, Frilling A, Paulson S. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Annals of Oncology 2020;31:202-12. [DOI: 10.1016/j.annonc.2019.11.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
15 Nikou AF, Tenzel NS, Hua P, Orbuch L, Orbuch IK. Appendectomy Should Be Performed During Minimally Invasive Surgery for Endometriosis. JSLS 2021;25:e2020. [PMID: 33880001 DOI: 10.4293/JSLS.2020.00095] [Reference Citation Analysis]
16 Malczewska A, Oberg K, Kos-Kudla B. NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis. Endocr Connect 2021;10:110-23. [PMID: 33289691 DOI: 10.1530/EC-20-0417] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Tomita T. Significance of chromogranin A and synaptophysin in medullary thyroid carcinoma. Bosn J Basic Med Sci 2021;21:535-41. [PMID: 33485291 DOI: 10.17305/bjbms.2020.5407] [Reference Citation Analysis]
18 Robbins HL, Symington M, Mosterman B, Tranter F, Davies L, Randeva HS, Penedo A, Ferreira C, Darby C, Grammatopoulos D, Kaltsas G, Weickert MO. Effects of intake of breakfast or caffeine-containing beverages on measurement of circulating chromogranin A in plasma. GastroHep 2019;1:11-21. [DOI: 10.1002/ygh2.208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]